-
2
-
-
0017076849
-
Oat cell carcinoma of the lung. Early treatment results of combination radiation therapy and chemotherapy
-
Hornback NB, Einhorn L, Shidnia H, Joe BT, Krause M, Furnas B. Oat cell carcinoma of the lung. Early treatment results of combination radiation therapy and chemotherapy. Cancer 1976;37:2658-2664.
-
(1976)
Cancer
, vol.37
, pp. 2658-2664
-
-
Hornback, N.B.1
Einhorn, L.2
Shidnia, H.3
Joe, B.T.4
Krause, M.5
Furnas, B.6
-
3
-
-
0022413561
-
Characteristics of long-term survivors after treatment for inoperable carcinoma of the lung
-
Komaki R, Cox JD, Hartz AJ, Byhardt RW, Perez-Tamayo C, Clowry L, et al. Characteristics of long-term survivors after treatment for inoperable carcinoma of the lung. Am J Clin Oncol 1985;8:362-370.
-
(1985)
Am J Clin Oncol
, vol.8
, pp. 362-370
-
-
Komaki, R.1
Cox, J.D.2
Hartz, A.J.3
Byhardt, R.W.4
Perez-Tamayo, C.5
Clowry, L.6
-
4
-
-
0036843105
-
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer
-
Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291.
-
(2002)
J Clin Oncol
, vol.20
, pp. 4285-4291
-
-
Scagliotti, G.V.1
De Marinis, F.2
Rinaldi, M.3
Crinò, L.4
Gridelli, C.5
Ricci, S.6
-
5
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer
-
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 2006;355:2542-2550.
-
(2006)
N Engl J Med
, vol.355
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
Brahmer, J.4
Schiller, J.H.5
Dowlati, A.6
-
6
-
-
33747847740
-
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IBIIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
-
Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IBIIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719-727.
-
(2006)
Lancet Oncol
, vol.7
, pp. 719-727
-
-
Douillard, J.Y.1
Rosell, R.2
De Lena, M.3
Carpagnano, F.4
Ramlau, R.5
Gonzáles-Larriba, J.L.6
-
7
-
-
33846794665
-
A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer
-
Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 2006;1:611-621.
-
(2006)
J Thorac Oncol
, vol.1
, pp. 611-621
-
-
Burdett, S.1
Stewart, L.A.2
Rydzewska, L.3
-
8
-
-
49049089802
-
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
-
Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3543-3551
-
-
Scagliotti, G.V.1
Parikh, P.2
Von Pawel, J.3
Biesma, B.4
Vansteenkiste, J.5
Manegold, C.6
-
9
-
-
15744362912
-
The 2004 World Health Organization classification of lung tumors
-
Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005;40:90-97.
-
(2005)
Semin Roentgenol
, vol.40
, pp. 90-97
-
-
Beasley, M.B.1
Brambilla, E.2
Travis, W.D.3
-
10
-
-
84875925170
-
New pathologic classification of lung cancer: relevance for clinical practice and clinical trials
-
Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013;31:992-1001.
-
(2013)
J Clin Oncol
, vol.31
, pp. 992-1001
-
-
Travis, W.D.1
Brambilla, E.2
Riely, G.J.3
-
11
-
-
0017287037
-
Regional immunotherapy of lung cancer with intrapleural B.C.G
-
McKneally MF, Maver C, Kausel HW. Regional immunotherapy of lung cancer with intrapleural B.C.G. Lancet 1976;1:377-379.
-
(1976)
Lancet
, vol.1
, pp. 377-379
-
-
McKneally, M.F.1
Maver, C.2
Kausel, H.W.3
-
12
-
-
0019985540
-
Regional immunotherapy in resectable squamous cell lung carcinoma. Analysis of a randomized study
-
Roeslin N, Lang JM, Morand G, Wihlm JM, Witz JP. Regional immunotherapy in resectable squamous cell lung carcinoma. Analysis of a randomized study. Cancer Immunol Immunother 1982;13:174-175.
-
(1982)
Cancer Immunol Immunother
, vol.13
, pp. 174-175
-
-
Roeslin, N.1
Lang, J.M.2
Morand, G.3
Wihlm, J.M.4
Witz, J.P.5
-
13
-
-
84904112296
-
Immunotherapy in the treatment of non-small cell lung cancer
-
Sundar R, Soong R, Cho BC, Brahmer JR, Soo RA. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014;85:101-109.
-
(2014)
Lung Cancer
, vol.85
, pp. 101-109
-
-
Sundar, R.1
Soong, R.2
Cho, B.C.3
Brahmer, J.R.4
Soo, R.A.5
-
14
-
-
0021888581
-
Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study
-
Maurer LH, Pajak T, Eaton W, Comis R, Chahinian P, Faulkner C, et al. Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study. J Clin Oncol 1985;3:969-976.
-
(1985)
J Clin Oncol
, vol.3
, pp. 969-976
-
-
Maurer, L.H.1
Pajak, T.2
Eaton, W.3
Comis, R.4
Chahinian, P.5
Faulkner, C.6
-
15
-
-
0022979412
-
Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial
-
Matthay RA, Mahler DA, Beck GJ, Loke J, Baue AE, Carter DC, et al. Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Res 1986;46:5963-5968.
-
(1986)
Cancer Res
, vol.46
, pp. 5963-5968
-
-
Matthay, R.A.1
Mahler, D.A.2
Beck, G.J.3
Loke, J.4
Baue, A.E.5
Carter, D.C.6
-
16
-
-
0026653868
-
Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer
-
Jansen RL, Slingerland R, Goey SH, Franks CR, Bolhuis RL, Stoter G. Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer. J Immunother (1991) 1992;12:70-73.
-
(1992)
J Immunother (1991)
, vol.12
, pp. 70-73
-
-
Jansen, R.L.1
Slingerland, R.2
Goey, S.H.3
Franks, C.R.4
Bolhuis, R.L.5
Stoter, G.6
-
17
-
-
0028926389
-
Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer
-
Schiller JH, Morgan-Ihrig C, Levitt ML. Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am J Clin Oncol 1995;18:47-51.
-
(1995)
Am J Clin Oncol
, vol.18
, pp. 47-51
-
-
Schiller, J.H.1
Morgan-Ihrig, C.2
Levitt, M.L.3
-
18
-
-
1542360632
-
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial
-
Lara PN Jr, Laptalo L, Longmate J, Lau DH, Gandour-Edwards R, Gumerlock PH, et al. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer 2004;5:231-236.
-
(2004)
Clin Lung Cancer
, vol.5
, pp. 231-236
-
-
Lara, P.N.1
Laptalo, L.2
Longmate, J.3
Lau, D.H.4
Gandour-Edwards, R.5
Gumerlock, P.H.6
-
19
-
-
16844375982
-
Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B
-
Clamon G, Herndon J, Kern J, Govindan R, Garst J, Watson D, et al. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer. 2005;103:1670-1675.
-
(2005)
Cancer
, vol.103
, pp. 1670-1675
-
-
Clamon, G.1
Herndon, J.2
Kern, J.3
Govindan, R.4
Garst, J.5
Watson, D.6
-
20
-
-
84892485531
-
Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer
-
Brahmer JR, Pardoll DM. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res. 2013;1:85-91.
-
(2013)
Cancer Immunol Res
, vol.1
, pp. 85-91
-
-
Brahmer, J.R.1
Pardoll, D.M.2
-
21
-
-
84919832561
-
Immunotherapy and lung cancer: current developments and novel targeted therapies
-
Domingues D, Turner A, Silva MD, Marques DS, Mellidez JC, Wannesson L, et al. Immunotherapy and lung cancer: current developments and novel targeted therapies. Immunotherapy 2014;6:1221-1235.
-
(2014)
Immunotherapy
, vol.6
, pp. 1221-1235
-
-
Domingues, D.1
Turner, A.2
Silva, M.D.3
Marques, D.S.4
Mellidez, J.C.5
Wannesson, L.6
-
22
-
-
44349150012
-
Inhibitory B7-family molecules in the tumour microenvironment
-
Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-477.
-
(2008)
Nat Rev Immunol
, vol.8
, pp. 467-477
-
-
Zou, W.1
Chen, L.2
-
23
-
-
84858766182
-
The blockade of immune checkpoints in cancer immunotherapy
-
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-264.
-
(2012)
Nat Rev Cancer
, vol.12
, pp. 252-264
-
-
Pardoll, D.M.1
-
24
-
-
84890980389
-
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
-
Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014;11:24-37.
-
(2014)
Nat Rev Clin Oncol
, vol.11
, pp. 24-37
-
-
Drake, C.G.1
Lipson, E.J.2
Brahmer, J.R.3
-
25
-
-
0026700235
-
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death
-
Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11:3887-3895.
-
(1992)
EMBO J
, vol.11
, pp. 3887-3895
-
-
Ishida, Y.1
Agata, Y.2
Shibahara, K.3
Honjo, T.4
-
26
-
-
27744560614
-
Alternative splice variants of the human PD-1 gene
-
Nielsen C, Ohm-Laursen L, Barington T, Husby S, Lillevang ST. Alternative splice variants of the human PD-1 gene. Cell Immunol 2005;235:109-116.
-
(2005)
Cell Immunol
, vol.235
, pp. 109-116
-
-
Nielsen, C.1
Ohm-Laursen, L.2
Barington, T.3
Husby, S.4
Lillevang, S.T.5
-
28
-
-
32544459770
-
Restoring function in exhausted CD8 T cells during chronic viral infection
-
Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-687.
-
(2006)
Nature
, vol.439
, pp. 682-687
-
-
Barber, D.L.1
Wherry, E.J.2
Masopust, D.3
Zhu, B.4
Allison, J.P.5
Sharpe, A.H.6
-
29
-
-
33947407689
-
Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression
-
Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007;81:2545-2553.
-
(2007)
J Virol
, vol.81
, pp. 2545-2553
-
-
Radziewicz, H.1
Ibegbu, C.C.2
Fernandez, M.L.3
Workowski, K.A.4
Obideen, K.5
Wehbi, M.6
-
30
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.
-
(2012)
N Engl J Med
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
McDermott, D.F.6
-
31
-
-
0032736029
-
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
-
Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365-1369.
-
(1999)
Nat Med
, vol.5
, pp. 1365-1369
-
-
Dong, H.1
Zhu, G.2
Tamada, K.3
Chen, L.4
-
32
-
-
5844264920
-
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
-
Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001;2:261-268.
-
(2001)
Nat Immunol
, vol.2
, pp. 261-268
-
-
Latchman, Y.1
Wood, C.R.2
Chernova, T.3
Chaudhary, D.4
Borde, M.5
Chernova, I.6
-
33
-
-
84879579673
-
At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
-
Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol 2013;94:25-39.
-
(2013)
J Leukoc Biol
, vol.94
, pp. 25-39
-
-
Intlekofer, A.M.1
Thompson, C.B.2
-
34
-
-
33745605153
-
B7- H3 and B7-H4 expression in non-small-cell lung cancer
-
Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, et al. B7- H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 2006;53:143-151.
-
(2006)
Lung Cancer
, vol.53
, pp. 143-151
-
-
Sun, Y.1
Wang, Y.2
Zhao, J.3
Gu, M.4
Giscombe, R.5
Lefvert, A.K.6
-
35
-
-
34247884612
-
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
-
Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007;8:239-245.
-
(2007)
Nat Immunol
, vol.8
, pp. 239-245
-
-
Sharpe, A.H.1
Wherry, E.J.2
Ahmed, R.3
Freeman, G.J.4
-
36
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-2465.
-
(2012)
N Engl J Med
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
Hwu, W.J.4
Topalian, S.L.5
Hwu, P.6
-
37
-
-
33846118474
-
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
-
Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13:84-88.
-
(2007)
Nat Med
, vol.13
, pp. 84-88
-
-
Parsa, A.T.1
Waldron, J.S.2
Panner, A.3
Crane, C.A.4
Parney, I.F.5
Barry, J.J.6
-
38
-
-
79952202494
-
Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway
-
Qin X, Liu C, Zhou Y, Wang G. Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway. Cell Mol Biol (Noisy-le-grand) 2010;56 Suppl:OL1366-OL1372.
-
(2010)
Cell Mol Biol (Noisy-le-grand)
, vol.56
, pp. OL1366-OL1372
-
-
Qin, X.1
Liu, C.2
Zhou, Y.3
Wang, G.4
-
39
-
-
58549102319
-
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7- H1)
-
Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7- H1). Proc Natl Acad Sci U S A 2008;105:20852-20857.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 20852-20857
-
-
Marzec, M.1
Zhang, Q.2
Goradia, A.3
Raghunath, P.N.4
Liu, X.5
Paessler, M.6
-
40
-
-
77953747963
-
The PD-1 pathway in tolerance and autoimmunity
-
Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-242.
-
(2010)
Immunol Rev
, vol.236
, pp. 219-242
-
-
Francisco, L.M.1
Sage, P.T.2
Sharpe, A.H.3
-
41
-
-
34347400169
-
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
-
Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007;110:296-304.
-
(2007)
Blood
, vol.110
, pp. 296-304
-
-
Liu, J.1
Hamrouni, A.2
Wolowiec, D.3
Coiteux, V.4
Kuliczkowski, K.5
Hetuin, D.6
-
42
-
-
31444451661
-
Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274)
-
Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 2006;580:755-762.
-
(2006)
FEBS Lett
, vol.580
, pp. 755-762
-
-
Lee, S.J.1
Jang, B.C.2
Lee, S.W.3
Yang, Y.I.4
Suh, S.I.5
Park, Y.M.6
-
43
-
-
84859128199
-
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
-
127ra137.
-
Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra137.
-
(2012)
Sci Transl Med
, vol.4
-
-
Taube, J.M.1
Anders, R.A.2
Young, G.D.3
Xu, H.4
Sharma, R.5
McMiller, T.L.6
-
44
-
-
18544380239
-
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
-
Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
-
(2002)
Nat Med
, vol.8
, pp. 793-800
-
-
Dong, H.1
Strome, S.E.2
Salomao, D.R.3
Tamura, H.4
Hirano, F.5
Flies, D.B.6
-
45
-
-
0038273853
-
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
-
Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9:562-567.
-
(2003)
Nat Med
, vol.9
, pp. 562-567
-
-
Curiel, T.J.1
Wei, S.2
Dong, H.3
Alvarez, X.4
Cheng, P.5
Mottram, P.6
-
46
-
-
33745491116
-
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance
-
Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006;108:19-24.
-
(2006)
Acta Histochem
, vol.108
, pp. 19-24
-
-
Wu, C.1
Zhu, Y.2
Jiang, J.3
Zhao, J.4
Zhang, X.G.5
Xu, N.6
-
47
-
-
33846852187
-
Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy
-
Thompson RH, Dong H, Kwon ED. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 2007;13:709s-715s.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 709s-715s
-
-
Thompson, R.H.1
Dong, H.2
Kwon, E.D.3
-
48
-
-
34247532726
-
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer
-
Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007;13:2151-2157.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2151-2157
-
-
Nomi, T.1
Sho, M.2
Akahori, T.3
Hamada, K.4
Kubo, A.5
Kanehiro, H.6
-
49
-
-
49649114804
-
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
-
Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:3044-3051.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 3044-3051
-
-
Berger, R.1
Rotem-Yehudar, R.2
Slama, G.3
Landes, S.4
Kneller, A.5
Leiba, M.6
-
50
-
-
33847611968
-
Programmed cell death 1 ligand 1 and tumorinfiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
-
Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumorinfiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007;104:3360-3365.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 3360-3365
-
-
Hamanishi, J.1
Mandai, M.2
Iwasaki, M.3
Okazaki, T.4
Tanaka, Y.5
Yamaguchi, K.6
-
51
-
-
80052476869
-
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
-
Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011;28:682-688.
-
(2011)
Med Oncol
, vol.28
, pp. 682-688
-
-
Mu, C.Y.1
Huang, J.A.2
Chen, Y.3
Chen, C.4
Zhang, X.G.5
-
52
-
-
84871966600
-
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer
-
Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73:128-138.
-
(2013)
Cancer Res
, vol.73
, pp. 128-138
-
-
Badoual, C.1
Hans, S.2
Merillon, N.3
Van Ryswick, C.4
Ravel, P.5
Benhamouda, N.6
-
53
-
-
84924048197
-
Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements
-
Teixidó C, Karachaliou N, Peg V, Gimenez-Capitan A, Rosell R. Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements. Transl Lung Cancer Res 2014;3:70-74.
-
(2014)
Transl Lung Cancer Res
, vol.3
, pp. 70-74
-
-
Teixidó, C.1
Karachaliou, N.2
Peg, V.3
Gimenez-Capitan, A.4
Rosell, R.5
-
55
-
-
84898476658
-
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
-
Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 2014;20:430-435.
-
(2014)
Nat Med
, vol.20
, pp. 430-435
-
-
Thierry, A.R.1
Mouliere, F.2
El Messaoudi, S.3
Mollevi, C.4
Lopez-Crapez, E.5
Rolet, F.6
-
56
-
-
84883027282
-
Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer
-
Pailler E, Adam J, Barthélémy A, Oulhen M, Auger N, Valent A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol 2013;31:2273-2281.
-
(2013)
J Clin Oncol
, vol.31
, pp. 2273-2281
-
-
Pailler, E.1
Adam, J.2
Barthélémy, A.3
Oulhen, M.4
Auger, N.5
Valent, A.6
-
57
-
-
84907497893
-
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
-
Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G, et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia 2014;28:2367-2375.
-
(2014)
Leukemia
, vol.28
, pp. 2367-2375
-
-
Rossille, D.1
Gressier, M.2
Damotte, D.3
Maucort-Boulch, D.4
Pangault, C.5
Semana, G.6
-
58
-
-
77954899030
-
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
-
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-3175.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3167-3175
-
-
Brahmer, J.R.1
Drake, C.G.2
Wollner, I.3
Powderly, J.D.4
Picus, J.5
Sharfman, W.H.6
-
59
-
-
84920655625
-
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
-
D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 2015;112:95-102.
-
(2015)
Br J Cancer
, vol.112
, pp. 95-102
-
-
D'Incecco, A.1
Andreozzi, M.2
Ludovini, V.3
Rossi, E.4
Capodanno, A.5
Landi, L.6
-
60
-
-
84923078390
-
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
-
Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558-562.
-
(2014)
Nature
, vol.515
, pp. 558-562
-
-
Powles, T.1
Eder, J.P.2
Fine, G.D.3
Braiteh, F.S.4
Loriot, Y.5
Cruz, C.6
-
61
-
-
84920956735
-
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
-
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-567.
-
(2014)
Nature
, vol.515
, pp. 563-567
-
-
Herbst, R.S.1
Soria, J.C.2
Kowanetz, M.3
Fine, G.D.4
Hamid, O.5
Gordon, M.S.6
-
62
-
-
84880736969
-
Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO- 4538)
-
abstr 3016.
-
Grosso J, Horak CE, Inzunza D, Cardona DM, Simon JS, Gupta AK, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO- 4538). J Clin Oncol 2013;31:abstr 3016.
-
(2013)
J Clin Oncol
, vol.31
-
-
Grosso, J.1
Horak, C.E.2
Inzunza, D.3
Cardona, D.M.4
Simon, J.S.5
Gupta, A.K.6
-
63
-
-
84929481480
-
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
-
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. N Engl J Med 2015;372:2018-2028.
-
(2015)
N Engl J Med
, vol.372
, pp. 2018-2028
-
-
Garon, E.B.1
Rizvi, N.A.2
Hui, R.3
Leighl, N.4
Balmanoukian, A.S.5
Eder, J.P.6
-
64
-
-
4243096258
-
B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
-
Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004;10:5094-5100.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 5094-5100
-
-
Konishi, J.1
Yamazaki, K.2
Azuma, M.3
Kinoshita, I.4
Dosaka-Akita, H.5
Nishimura, M.6
-
65
-
-
84904024273
-
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
-
Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064-5074.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 5064-5074
-
-
Taube, J.M.1
Klein, A.2
Brahmer, J.R.3
Xu, H.4
Pan, X.5
Kim, J.H.6
-
66
-
-
84890020587
-
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
-
Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013;3:1355-1363.
-
(2013)
Cancer Discov
, vol.3
, pp. 1355-1363
-
-
Akbay, E.A.1
Koyama, S.2
Carretero, J.3
Altabef, A.4
Tchaicha, J.H.5
Christensen, C.L.6
-
67
-
-
84937563758
-
PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
-
Ji M, Liu Y, Li Q, Li XD, Zhao WQ, Zhang H, et al. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. J Transl Med 2015;13:5.
-
(2015)
J Transl Med
, vol.13
, pp. 5
-
-
Ji, M.1
Liu, Y.2
Li, Q.3
Li, X.D.4
Zhao, W.Q.5
Zhang, H.6
-
68
-
-
84937549213
-
Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies
-
Yang LL, Wu YL. Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies. Lung Cancer Management 2014;3:175-190.
-
(2014)
Lung Cancer Management
, vol.3
, pp. 175-190
-
-
Yang, L.L.1
Wu, Y.L.2
-
69
-
-
84937578507
-
Immunotherapy in lung cancer
-
Massarelli E, Papadimitrakopoulou V, Welsh J, Tang C, Tsao A. Immunotherapy in lung cancer. Transl Lung Cancer Res 2014;3:53-63.
-
(2014)
Transl Lung Cancer Res
, vol.3
, pp. 53-63
-
-
Massarelli, E.1
Papadimitrakopoulou, V.2
Welsh, J.3
Tang, C.4
Tsao, A.5
-
70
-
-
84879625854
-
New checkpoint inhibitors ride the immunotherapy tsunami
-
Mullard A. New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov 2013;12:489-492.
-
(2013)
Nat Rev Drug Discov
, vol.12
, pp. 489-492
-
-
Mullard, A.1
-
71
-
-
79955518331
-
Overall survival and PD-L1 expression in metastasized malignant melanoma
-
Gadiot J, Hooijkaas AI, Kaiser AD, van Tinteren H, van Boven H, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011;117:2192-2201.
-
(2011)
Cancer
, vol.117
, pp. 2192-2201
-
-
Gadiot, J.1
Hooijkaas, A.I.2
Kaiser, A.D.3
Van Tinteren, H.4
Van Boven, H.5
Blank, C.6
-
72
-
-
84937619784
-
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
-
Google Patents
-
Cogswell JP, Goldberg SM, Gupta AK, Jure-Kunkel M, Wang XT, Wigginton JM. Cancer immunotherapy by disrupting pd-1/pd-l1 signaling. Google Patents; 2013: WO 2013173223 A1.
-
(2013)
-
-
Cogswell, J.P.1
Goldberg, S.M.2
Gupta, A.K.3
Jure-Kunkel, M.4
Wang, X.T.5
Wigginton, J.M.6
-
73
-
-
84937579282
-
Antibodies that bind to human programmed death ligand 1 (pd-l1)
-
Google Patents
-
Pierce RH, Bourne P, Liang L, Bigler M. Antibodies that bind to human programmed death ligand 1 (pd-l1). Google Patents; 2014: WO 2014100079 A1.
-
(2014)
-
-
Pierce, R.H.1
Bourne, P.2
Liang, L.3
Bigler, M.4
-
74
-
-
84920956732
-
PD-1 blockade induces responses by inhibiting adaptive immune resistance
-
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568-571.
-
(2014)
Nature
, vol.515
, pp. 568-571
-
-
Tumeh, P.C.1
Harview, C.L.2
Yearley, J.H.3
Shintaku, I.P.4
Taylor, E.J.5
Robert, L.6
-
75
-
-
84920937027
-
Clinical Activity and Safety of MEDI4736, an Anti-PD-L1 Antibody, in Patients with Head and Neck Cancer
-
Fury M, Ou SH, Balmanoukian A, Hansen A, Massarelli E, Blake-Haskins A, et al. Clinical Activity and Safety of MEDI4736, an Anti-PD-L1 Antibody, in Patients with Head and Neck Cancer. Ann Oncol 2014;25:iv340-iv356.
-
(2014)
Ann Oncol
, vol.25
, pp. iv340-iv356
-
-
Fury, M.1
Ou, S.H.2
Balmanoukian, A.3
Hansen, A.4
Massarelli, E.5
Blake-Haskins, A.6
-
76
-
-
84892866206
-
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma
-
Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 2013;31:4311-4318.
-
(2013)
J Clin Oncol
, vol.31
, pp. 4311-4318
-
-
Weber, J.S.1
Kudchadkar, R.R.2
Yu, B.3
Gallenstein, D.4
Horak, C.E.5
Inzunza, H.D.6
|